ARTICLE | Finance
Seeking alpha
Radioimmunotherapy play Actinium adds CEO, seeks bridge round before going public
August 27, 2012 7:00 AM UTC
After adding a CEO with experience in guiding companies to the public market, Actinium Pharmaceuticals Inc. is now looking to complete a $15-$20 million bridge financing that will, if all goes to plan, be followed closely by a reverse merger this fall.
The radioimmunotherapy company's twin objectives, according to President and CEO Jack Talley, are to both raise the money to conduct trials in two programs for acute myelogenous leukemia (AML) and boost the company's profile in the eyes of potential partners...